PTO Form 1553 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
Trademark/Service Mark Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
85566635 |
LAW OFFICE ASSIGNED |
LAW OFFICE 110 |
EXTENSION OF USE |
YES |
MARK SECTION |
MARK |
http://uspto.report/TM/85566635/mark.png |
LITERAL ELEMENT |
AILERON |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
MARK STATEMENT |
The mark consists of standard characters, without claim to any particular font style, size or color. |
OWNER SECTION |
NAME |
Aileron Therapeutics, Inc. |
STREET |
281 Albany Street |
CITY |
Cambridge |
STATE |
Massachusetts |
ZIP/POSTAL CODE |
02139 |
COUNTRY |
United States |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
pharmaceutical compositions, namely, preparations for the treatment of obesity, cancer, diabetes, neurodegenerative disorders, cardiovascular
disease and disorders, metabolic syndrome, autoimmune disorders, central nervous system diseases and disorders, neurological disorders, urological disorders, gastrointestinal disorders,
musculoskeletal disorders, allergies, hypertension, erectile dysfunction, sexual dysfunction, stroke, migraines, pain, inflammation and inflammatory diseases, respiratory and infectious diseases,
immunological disorders, anxiety, depression, neuropsychiatric disorders including both psychotic and non-psychotic conditions, and substance abuse disorders, including both abuse and dependence,
disorders of blood cell production, organ transplant rejection, endocrinologic disorders, and bacterial, viral and fungal diseases; diagnostic products, namely, medical diagnostic reagents,
diagnostic reagents for clinical or medical laboratory use; biological reagents for medical purposes in the field of molecular biology; reagents for use in biological processing for medical
purposes |
GOODS OR SERVICES DELETED FROM THE APPLICATION |
obesity, diabetes, neurodegenerative disorders, cardiovascular disease and disorders, metabolic syndrome, autoimmune disorders, central
nervous system diseases and disorders, neurological disorders, urological disorders, gastrointestinal disorders, musculoskeletal disorders, allergies, hypertension, erectile dysfunction, sexual
dysfunction, stroke, migraines, pain, inflammation and inflammatory diseases, respiratory and infectious diseases, immunological disorders, anxiety, depression, neuropsychiatric disorders including
both psychotic and non-psychotic conditions, and substance abuse disorders, including both abuse and dependence, disorders of blood cell production, organ transplant rejection, endocrinologic
disorders, and bacterial, viral and fungal diseases; diagnostic products, namely, medical diagnostic reagents, diagnostic reagents for clinical or medical laboratory use; biological reagents for
medical purposes in the field of molecular biology; reagents for use in biological processing for medical purposes |
GOODS OR SERVICES IN USE IN COMMERCE |
pharmaceutical compositions, namely, preparations for the treatment of cancer |
FIRST USE ANYWHERE DATE |
08/16/2010 |
FIRST USE IN COMMERCE DATE |
01/00/2015 |
SPECIMEN FILE NAME(S) |
ORIGINAL PDF FILE |
SPN0-1286104150-20150319171829016029_._AILERON_Specimen.pdf |
CONVERTED PDF FILE(S)
(1 page) |
\\TICRS\EXPORT16\IMAGEOUT16\855\666\85566635\xml20\SOU0002.JPG |
SPECIMEN DESCRIPTION |
picture of the mark on a product label |
REQUEST TO DIVIDE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES IN USE |
1 |
SUBTOTAL AMOUNT [ALLEGATION OF USE FEE] |
100 |
TOTAL AMOUNT |
100 |
SIGNATURE SECTION |
DECLARATION SIGNATURE |
/Allen Annis, Ph.D./ |
SIGNATORY'S NAME |
Allen Annis, Ph.D. |
SIGNATORY'S POSITION |
Vice President, Biophysical and Analytical Technologies |
DATE SIGNED |
03/23/2015 |
SIGNATORY'S PHONE NUMBER |
Not Required |
FILING INFORMATION |
SUBMIT DATE |
Mon Mar 23 14:14:44 EDT 2015 |
TEAS STAMP |
USPTO/SOU-XX.XX.XXX.XXX-2
0150323141444613555-85566
635-53027a547fd24705440ba
6373c28885b4fd2ac3db80eac
2ac8cc0c9331c428296-DA-50
9-20150319220705301543 |
PTO Form 1553 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
Trademark/Service Mark Statement of Use
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: AILERON(Standard Characters, see http://uspto.report/TM/85566635/mark.png)
SERIAL NUMBER: 85566635
An Extension of Time form is being filed with the Allegation of Use.
The applicant, Aileron Therapeutics, Inc., having an address of
281 Albany Street
Cambridge, Massachusetts 02139
United States
is submitting the following allegation of use information:
For International Class 005:
Current identification: pharmaceutical compositions, namely, preparations for the treatment of obesity, cancer, diabetes, neurodegenerative disorders, cardiovascular disease and disorders, metabolic
syndrome, autoimmune disorders, central nervous system diseases and disorders, neurological disorders, urological disorders, gastrointestinal disorders, musculoskeletal disorders, allergies,
hypertension, erectile dysfunction, sexual dysfunction, stroke, migraines, pain, inflammation and inflammatory diseases, respiratory and infectious diseases, immunological disorders, anxiety,
depression, neuropsychiatric disorders including both psychotic and non-psychotic conditions, and substance abuse disorders, including both abuse and dependence, disorders of blood cell production,
organ transplant rejection, endocrinologic disorders, and bacterial, viral and fungal diseases; diagnostic products, namely, medical diagnostic reagents, diagnostic reagents for clinical or medical
laboratory use; biological reagents for medical purposes in the field of molecular biology; reagents for use in biological processing for medical purposes
This
allegation of use does
NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these
goods/services are
permanently deleted: obesity, diabetes, neurodegenerative disorders, cardiovascular disease and disorders, metabolic syndrome, autoimmune disorders, central nervous system
diseases and disorders, neurological disorders, urological disorders, gastrointestinal disorders, musculoskeletal disorders, allergies, hypertension, erectile dysfunction, sexual dysfunction, stroke,
migraines, pain, inflammation and inflammatory diseases, respiratory and infectious diseases, immunological disorders, anxiety, depression, neuropsychiatric disorders including both psychotic and
non-psychotic conditions, and substance abuse disorders, including both abuse and dependence, disorders of blood cell production, organ transplant rejection, endocrinologic disorders, and bacterial,
viral and fungal diseases; diagnostic products, namely, medical diagnostic reagents, diagnostic reagents for clinical or medical laboratory use; biological reagents for medical purposes in the field
of molecular biology; reagents for use in biological processing for medical purposes
The mark is in use in commerce on or in connection with the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class:
pharmaceutical compositions, namely, preparations for the treatment of cancer
The mark was first used by the applicant, or the applicant's related company, licensee, or predecessor in interest at least as early as 08/16/2010, and first used in commerce at least as early as
01/00/2015, and is now in use in such commerce. The applicant is submitting one specimen for the class showing the mark as used in commerce on or in connection with any item in the class, consisting
of a(n) picture of the mark on a product label.
Original PDF file:
SPN0-1286104150-20150319171829016029_._AILERON_Specimen.pdf
Converted PDF file(s) (1 page)
Specimen File1
The applicant is not filing a Request to Divide with this Allegation of Use form.
A fee payment in the amount of $100 will be submitted with the form, representing payment for the allegation of use for 1 class.
Declaration
STATEMENTS: The signatory believes that: if the applicant is filing the amendment to allege use under 15 U.S.C. Section 1051(c) or a statement of use under 15 U.S.C. Section 1051(d), the applicant is
the owner of the trademark/service mark sought to be registered; the applicant or the applicant's related company or licensee is using the mark in commerce on or in connection with all the
goods/services in the application or notice of allowance, or as subsequently modified, and such use by the applicant's related company or licensee inures to the benefit of the applicant; that to the
best of the signatory's knowledge and belief, no other person has the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in
connection with the goods/services of such other person, to cause confusion or mistake, or to deceive; and the specimen(s) shows the mark as used on or in connection with the goods/services in
commerce.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false
statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and
that all statements made on information and belief are believed to be true.
Signature: /Allen Annis, Ph.D./ Date Signed: 03/23/2015
Signatory's Name: Allen Annis, Ph.D.
Signatory's Position: Vice President, Biophysical and Analytical Technologies
Signatory's Phone: Not Required
RAM Sale Number: 85566635
RAM Accounting Date: 03/24/2015
Serial Number: 85566635
Internet Transmission Date: Mon Mar 23 14:14:44 EDT 2015
TEAS Stamp: USPTO/SOU-XX.XX.XXX.XXX-2015032314144461
3555-85566635-53027a547fd24705440ba6373c
28885b4fd2ac3db80eac2ac8cc0c9331c428296-
DA-509-20150319220705301543